Pinter, A, Brnabic, A, Trovato, E, Puig, L, Carrascosa, JM, Boye, T, Megna, M, Sabatino, S, de la Torre, I, Maul, JT. Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatology and Therapy. 2025; 15(10)DOI:10.1007/s13555-025-01494-z. PMID:40699538. IF:4.200(Q1/1D).

Bouhatous, YM, Bredrup, C, Maurer, A, Mirakovska, L, Foster, A, Kosaki, K, Jost, C, Demoulin, JB, Luu, M, Vabres, P, Kurtz, JE, Schaefer, E, Guimier, A, Cormier-Daire, V, Lim, D, Thompson, S, Olson, L, Kwon, HR, Aguirre-Rodriguez, C, Hernandez-Dorronsoro, U, Martinez-Soroa, I, Iznardo, H, Mascaro, JMJ, Baselga, E, Kalantari, S, Mussa, A, Gazzin, A, Carli, D, Svinvik, I, Mutlu-Albayrak, H, Bluefeather, S, Zarate, Y, Takenouchi, T, Naicker, T, Chateau, A, Gokhul, A, Dube-Pule, A, Haniffa, M, Peitee, WO, Nordgren, A, Carpentier, M, Binquet, C, Briffaut, AS, Bal, L, Pond, D, Rustad, CF, Bardou, M, Faivre, L. 'Knowing and Treating Kosaki/Penttinen syndrome' international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors. JOURNAL OF MEDICAL GENETICS. 2025; 62(10)DOI:10.1136/jmg-2024-110600. PMID:40707250. IF:3.700(Q2/3D).

Yosipovitch, G, Lio, PA, Rosmarin, D, Legat, FJ, Serra-Baldrich, E, Carrascosa, JM, Bardolet, L, Crane, H, Casillas, M, Pierce, E, Zhong, JL, Elmaraghy, H, Ständer, S. Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. DERMATOLOGY. 2025; 241(4)DOI:10.1159/000547142. PMID:40602386. IF:2.700(Q2/4D).

Puig, L. Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy. LANCET. 2025; 406(10510)DOI:10.1016/S0140-6736(25)01675-7. PMID:40976247. IF:88.500(Q1/1D).

Ferrer, AL, Macias, HC, Sanz, LP, Alonso, AL. Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.06.013. PMID:40570946. IF:(Q/D).

Puig, L, Sewerin, P, Schuster, C, Ng, KJ, Papadimitropoulos, M, Gadagamma, S, Nuñez, M, Lampropoulou, A. Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023. ADVANCES IN THERAPY. 2025; 42(9)DOI:10.1007/s12325-025-03258-9. PMID:40676380. IF:4.000(Q1/3D).

Kokolakis, G, Vilarrasa, E, Garg, A, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, BM, Guillem, P. Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey. Jeadv Clinical Practice. 2025; 4(4)DOI:10.1002/jvc2.70071. PMID:. IF:(Q/D).

Papp, KA, Lebwohl, MG, Puig, L, Ohtsuki, M, Beissert, S, Gooderham, M, Amin, AZ, Wu, TS, Rubant, S, Bialik, B, Ashley, D, Soliman, AM, Chen, MM, Blauvelt, A. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; 26(5)DOI:10.1007/s40257-025-00964-6. PMID:40728772. IF:8.800(Q1/1D).